Your browser doesn't support javascript.
Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study.
Rashidi, Farid; Barco, Stefano; Kamangar, Farin; Heresi, Gustavo A; Emadi, Ashkan; Kaymaz, Cihangir; Jansa, Pavel; Reis, Abilio; Rashidi, Arash; Taghizadieh, Ali; Rezaeifar, Parisa; Moghimi, Minoosh; Ghodrati, Samad; Mozafari, Abolfazl; Foumani, Ali Alavi; Tahamtan, Ouria; Rafiee, Effat; Abbaspour, Zahra; Khodadadi, Kasra; Alamdari, Golsa; Boodaghi, Yasman; Rezaei, Maryam; Muhammadi, Muhammad Javad; Abbasi, Meysam; Movaseghi, Fatemeh; Koohi, Ata; Shakourzad, Leila; Ebrahimi, Fatemeh; Radvar, Sarvin; Amoozadeh, Maryam; Fereidooni, Fatemeh; Naseari, Hanieh; Movalled, Kobra; Ghorbani, Ozra; Ansarin, Khalil.
  • Rashidi F; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: fr2652@yahoo.com.
  • Barco S; Center for Thrombosis and Hemostasis, Johannes Gutenberg University Mainz, Mainz, Germany; Clinic of Angiology, University Hospital Zurich, Zurich, Switzerland.
  • Kamangar F; Department of Biology, School of Computer, Mathematical, and Natural Sciences, Morgan State University, Baltimore, MD, USA.
  • Heresi GA; Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, OH, USA.
  • Emadi A; Department of Medicine, School of Medicine, University of Maryland, Baltimore, USA; Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.
  • Kaymaz C; Department of Cardiology, Kosuyolu Heart Education and Research Hospital, University of Health Sciences, 34844 Istanbul, Turkey.
  • Jansa P; 2nd Department of Medicine - Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
  • Reis A; Pulmonary Vascular Disease Unit, Medicine Department, Centro Hospitalar Universitário do Porto, Porto, Portugal.
  • Rashidi A; Division of Nephrology and Hypertension, University Hospitals Cleveland Medical Center Cleveland, OH, USA.
  • Taghizadieh A; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rezaeifar P; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Moghimi M; Department of Hematology & Medical Oncology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Ghodrati S; Department of Pulmonology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Mozafari A; Department of Internal Medical, Qom Branch, Islamic Azad University, Qom, Iran.
  • Foumani AA; Inflammatory Lung Disease Research Center, Department of Internal Medicine, Razi Hospital, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Tahamtan O; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rafiee E; Department of Pulmonology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Abbaspour Z; Department of Endocrinology, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Khodadadi K; Department of Internal Medicine, Vali-e-Asr Hospital, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Alamdari G; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Boodaghi Y; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Rezaei M; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Muhammadi MJ; Student Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Abbasi M; Student Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Movaseghi F; Department of Internal Medical, Qom Branch, Islamic Azad University, Qom, Iran.
  • Koohi A; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Shakourzad L; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ebrahimi F; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Radvar S; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Amoozadeh M; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Fereidooni F; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Naseari H; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Movalled K; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ghorbani O; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  • Ansarin K; Tuberculosis and Lung Disease Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Thromb Res ; 198: 135-138, 2021 02.
Article in English | MEDLINE | ID: covidwho-971736
ABSTRACT

BACKGROUND:

Thrombosis and pulmonary embolism appear to be major causes of mortality in hospitalized coronavirus disease 2019 (COVID-19) patients. However, few studies have focused on the incidence of venous thromboembolism (VTE) after hospitalization for COVID-19.

METHODS:

In this multi-center study, we followed 1529 COVID-19 patients for at least 45 days after hospital discharge, who underwent routine telephone follow-up. In case of signs or symptoms of pulmonary embolism (PE) or deep vein thrombosis (DVT), they were invited for an in-hospital visit with a pulmonologist. The primary outcome was symptomatic VTE within 45 days of hospital discharge.

RESULTS:

Of 1529 COVID-19 patients discharged from hospital, a total of 228 (14.9%) reported potential signs or symptoms of PE or DVT and were seen for an in-hospital visit. Of these, 13 and 12 received Doppler ultrasounds or pulmonary CT angiography, respectively, of whom only one patient was diagnosed with symptomatic PE. Of 51 (3.3%) patients who died after discharge, two deaths were attributed to VTE corresponding to a 45-day cumulative rate of symptomatic VTE of 0.2% (95%CI 0.1%-0.6%; n = 3). There was no evidence of acute respiratory distress syndrome (ARDS) in these patients. Other deaths after hospital discharge included myocardial infarction (n = 13), heart failure (n = 9), and stroke (n = 9).

CONCLUSIONS:

We did not observe a high rate of symptomatic VTE in COVID-19 patients after hospital discharge. Routine extended thromboprophylaxis after hospitalization for COVID-19 may not have a net clinical benefit. Randomized trials may be warranted.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Discharge / Pulmonary Embolism / Venous Thrombosis / Venous Thromboembolism / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Thromb Res Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Patient Discharge / Pulmonary Embolism / Venous Thrombosis / Venous Thromboembolism / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: English Journal: Thromb Res Year: 2021 Document Type: Article